Released May 9, 2023, after the close
10-Q filed May 9, 2023, 39 days after period end · 0001162194-23-000024
Q1 2023 · 10-Q
Revenue$25.12M$25.12M −5.2% vs Q1 2022−7.0% vs Q4 2022
Net Income-$16.84M-$16.84M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.21-$0.21 N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit$12,281,000—
Operating Income-$16,593,000N/M
Operating Cash Flow-$8,485,000N/M
Free Cash Flowderived-$9,495,000N/M
Margins · derived
Gross margin48.9%
Operating margin-66.1%+37.7 pt vs Q1 2022
Net margin-67.1%+220.8 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $25.12M | $26.50M | $32.79M | $27.62M |
| Net Income | -$16.84M | -$76.29M | -$18.82M | -$15.98M |
| EPS Diluted | -$0.21 | -$0.99 | -$0.25 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR